Clinical Perspectives to Overcome Acquired Resistance to Anti–Programmed Death-1 and Anti–Programmed Death Ligand-1 Therapy in Non-Small Cell Lung Cancer

Immune checkpoint inhibitors have changed the paradigm of treatment options for non-small cell lung cancer (NSCLC). Monoclonal antibodies targeting programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) have gained wide attention for their application, which has been shown to result in prol...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Yong Jun, Lee, Jii Bum, Ha, Sang-Jun, Kim, Hye Ryun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society for Molecular and Cellular Biology 2021
Materias:
Minireview
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8175154/
https://www.ncbi.nlm.nih.gov/pubmed/34001680
http://dx.doi.org/10.14348/molcells.2021.0044

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8175154/
https://www.ncbi.nlm.nih.gov/pubmed/34001680
http://dx.doi.org/10.14348/molcells.2021.0044

Ejemplares similares